The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
- 1 September 2001
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (9), 2201-2210
- https://doi.org/10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Role of CD47 as a Marker of Self on Red Blood CellsScience, 2000
- Cellular and molecular mechanisms of action of bisphosphonatesCancer, 2000
- Management of corticosteroid-induced osteoporosisSeminars in Arthritis and Rheumatism, 2000
- Goals of treatment for paget's disease of boneJournal of Bone and Mineral Research, 1999
- Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelinesClinical Therapeutics, 1999
- Long‐term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate‐containing liposomesArthritis & Rheumatism, 1995
- Studies on liposome formulations for intra-articular delivery of clodronateJournal of Controlled Release, 1995
- The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the ratClinical and Experimental Immunology, 1995
- Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applicationsJournal of Immunological Methods, 1994
- Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.JCI Insight, 1991